ppanPersonalized Psychiatry and NeurologyPersonalized Psychiatry and Neurology2712-9179V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)10.52667/2712-9179-2022-2-2-57-66ppan-52Research ArticleREVIEWApplication of Antipsychotic Medication: Gender Differences in Tolerance and Medication ResponseGorobetsL. N.

Ludmila N. Gorobets

119034 Moscow

Tel.: +7-495-063-14-13

gorobetsln@mail.ruSemenovaN. D.

Natalia D. Semenova

119034 Moscow

LitvinovA. V.

Alexander V. Litvinov

119034 Moscow

Moscow Research Institute of Psychiatry – a branch of V. Serbsky National Medical Re-search Centre for Psychiatry and NarcologyRussian Federation202215112022225766Copyright © Gorobets L.N., Semenova N.D., Litvinov A.V., 20222022Gorobets L.N., Semenova N.D., Litvinov A.V.Gorobets L.N., Semenova N.D., Litvinov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jppn.ru/jour/article/view/52

This paper covers the role of gender factor in the efficacy and tolerance of antipsychotic therapy in patients with schizophrenic spectrum disorders. The author describes phenomenology of definitions that characterizes differences between male and female sexes. The authors give the data on biological basis of gender differences, frequency of occurrence and clinical features of neuroendocrine dysfunctions (NED) in patients with schizophrenic spectrum disorders during the therapy by first and second generations antipsychotics. It is shown that female patients are more “vulnerable” for some NED. It is emphasized that the problem of tolerance is now more relevant and significant in comparison with the efficacy of antipsychotics, because intolerance or poor tolerance are one of the most common reasons for non-adherence to therapy up to the complete abandonment of it.

schizophrenic spectrum disordersgender factorantipsychotic therapyneuroendocrine dysfunctionsReferencesAvedisova, A.S; Akhapkin, R.V. Problems of clinical assessment of the tolerability of therapy with psychotropic drugs. Psychiatry and Psychopharmacotherapy. P.B. Gannushkin Journal. 2005, 1(7): 17-20 (In Russ.).Avedisova, A.S; Akhapkin, R.V. Problems of clinical assessment of the tolerability of therapy with psychotropic drugs. Psychiatry and Psychopharmacotherapy. P.B. Gannushkin Journal. 2005, 1(7): 17-20 (In Russ.).Gorobets, L.N. Endocrinological aspects of the problem of tolerability of neuroleptic therapy in patients with schizophrenia (age and gender characteristics). Psychiatry and Psychopharmacotherapy. P.B. Gannushkin Journal. 2012, 14 (1): 1-47 (In Russ.).Gorobets, L.N. Endocrinological aspects of the problem of tolerability of neuroleptic therapy in patients with schizophrenia (age and gender characteristics). Psychiatry and Psychopharmacotherapy. P.B. Gannushkin Journal. 2012, 14 (1): 1-47 (In Russ.).Krasnov, V.N.; Gurovicha, I.Ia. Clinical guidelines: models for the diagnosis and treatment of mental and behavioral disorders. Social and Clinical Psychiatry. 1999 (In Russ.).Krasnov, V.N.; Gurovicha, I.Ia. Clinical guidelines: models for the diagnosis and treatment of mental and behavioral disorders. Social and Clinical Psychiatry. 1999 (In Russ.).Cadenhead, K.S. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res. 2011. 188(2): 208-216.Cadenhead, K.S. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res. 2011. 188(2): 208-216.Moriarty, P.J.; Lieber, D.; Bennett, A. et al. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr. Bull. 2001, 27(1): 103-113.Moriarty, P.J.; Lieber, D.; Bennett, A. et al. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr. Bull. 2001, 27(1): 103-113.Crespo-Facorro, B.; Pelayo-Terán, J.M.; Pérez-Iglesias, R. et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J. Psychiatr. Res. 2007, 41(8):659-666.Crespo-Facorro, B.; Pelayo-Terán, J.M.; Pérez-Iglesias, R. et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J. Psychiatr. Res. 2007, 41(8):659-666.Smith, S. Gender differences in antipsychotic prescribing. Int. Rev. Psychiatry. 2010, 22(5): 472-484.Smith, S. Gender differences in antipsychotic prescribing. Int. Rev. Psychiatry. 2010, 22(5): 472-484.Stewart, M. Narrative literature review: sexual dysfunction in the patient on hemodialysis. Nephrol. Nurs J. 2006. 33(6): 631-641.Stewart, M. Narrative literature review: sexual dysfunction in the patient on hemodialysis. Nephrol. Nurs J. 2006. 33(6): 631-641.Ilin, E.P. Pol i gender. Piter. 2010. http://www.Litres.ru/evgeniy-ilin/pol-i-gender (In Russ.).Ilin, E.P. Pol i gender. Piter. 2010. http://www.Litres.ru/evgeniy-ilin/pol-i-gender (In Russ.).Groleger, U.; Novak-Grubic, V. Gender, psychosis and psychotropic drugs: differences and similarities. Psychiatr Danub. 2010, 22(2): 338-342.Groleger, U.; Novak-Grubic, V. Gender, psychosis and psychotropic drugs: differences and similarities. Psychiatr Danub. 2010, 22(2): 338-342.Haack, S.; Seeringer, A.; Thürmann, P.A. et al. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009. 10(9): 1511-1526.Haack, S.; Seeringer, A.; Thürmann, P.A. et al. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009. 10(9): 1511-1526.Kolakowska, T.; Williams, A.O.; Ardern, M. et al. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br. J. Psychiatry. 1985, 146: 229-239.Kolakowska, T.; Williams, A.O.; Ardern, M. et al. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br. J. Psychiatry. 1985, 146: 229-239.Royal Australian and New Zealand College of Psychiatrists. Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Aust. N. Z. J. Psychiatry. 2005, 39(1-2): 1-30.Royal Australian and New Zealand College of Psychiatrists. Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Aust. N. Z. J. Psychiatry. 2005, 39(1-2): 1-30.Williams, O.; Coppolino, M.; George, S.R. et al. Sex differences in dopamine receptors and relevance to neuropsychiatric disorders. Brain Sci. 2021, 11(9): 1199.Williams, O.; Coppolino, M.; George, S.R. et al. Sex differences in dopamine receptors and relevance to neuropsychiatric disorders. Brain Sci. 2021, 11(9): 1199.Gorobets, L.N. Neuroendocrine disorders and neuroleptic therapy. Moscow: Medpractice-M”. 2007 (In Russ.).Gorobets, L.N. Neuroendocrine disorders and neuroleptic therapy. Moscow: Medpractice-M”. 2007 (In Russ.).Aichhorn, W.; Gasser, M.; Weiss, E.M. еt al. Gender differences in pharmacokinetics and side effects of second-generation antipsychotic drugs. Current Neuropharmacology. 2005, 3, 73-85.Aichhorn, W.; Gasser, M.; Weiss, E.M. еt al. Gender differences in pharmacokinetics and side effects of second-generation antipsychotic drugs. Current Neuropharmacology. 2005, 3, 73-85.Zhang, X.Y.; Chen, D.C.; Xiu, M.H. et al. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J. Clin. Psychiatry. 2012, 73(7): 1025-1033.Zhang, X.Y.; Chen, D.C.; Xiu, M.H. et al. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J. Clin. Psychiatry. 2012, 73(7): 1025-1033.Androutsos, Ch. Schizophrenia in children and adolescents: relevance and differentiation from adult schizophrenia. Psychiatriki. 2012, 23(1): 82-93.Androutsos, Ch. Schizophrenia in children and adolescents: relevance and differentiation from adult schizophrenia. Psychiatriki. 2012, 23(1): 82-93.Flier, J.S.; Maratos-Flier, E. Leptin's physiologic role: Does the emperor of energy balance have no clothes? Cell. Metab. 2017, 26(1): 24-26.Flier, J.S.; Maratos-Flier, E. Leptin's physiologic role: Does the emperor of energy balance have no clothes? Cell. Metab. 2017, 26(1): 24-26.Suzuki, T.; Remington, G.; Uchida, H. et al. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging. 2011, 28(12): 961-980.Suzuki, T.; Remington, G.; Uchida, H. et al. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging. 2011, 28(12): 961-980.Melkersson, K.; Hulting, A.L.; Hall, K. Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuroendocrinological Letter. 1999, 20, 199-204.Melkersson, K.; Hulting, A.L.; Hall, K. Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuroendocrinological Letter. 1999, 20, 199-204.Szymanski, S.; Lieberman, J.A.; Alvir, J.M. et al. Gender differences in onset of illness, treatment response, course, and biological indexes in first-episode schizophrenia patients. Am. J. Psychiatry. 1995, 152: 698-703.Szymanski, S.; Lieberman, J.A.; Alvir, J.M. et al. Gender differences in onset of illness, treatment response, course, and biological indexes in first-episode schizophrenia patients. Am. J. Psychiatry. 1995, 152: 698-703.Gogos, J.A. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder. Int. Rev. Neurobiol. 2007, 78: 397-422.Gogos, J.A. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder. Int. Rev. Neurobiol. 2007, 78: 397-422.Baeza, I.; Castro-Fornieles, J.; Deulofeu, R. et al. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Psychiatry Res. 2009, 168(2): 110-118.Baeza, I.; Castro-Fornieles, J.; Deulofeu, R. et al. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Psychiatry Res. 2009, 168(2): 110-118.Rajkumar, R.P. Prolactin and psychopathology in schizophrenia: a literature review and reappraisal. Schizophr. Res. Treatment. 2014, 175360, https://doi:10.1155/2014/175360.Rajkumar, R.P. Prolactin and psychopathology in schizophrenia: a literature review and reappraisal. Schizophr. Res. Treatment. 2014, 175360, https://doi:10.1155/2014/175360.Soares, B.G.; Lima, M.S. Penfluridol for schizophrenia. Cochrane Database Syst. Rev. 2006, (2): CD002923. https://doi:10.1002/14651858.CD002923.pub2.Soares, B.G.; Lima, M.S. Penfluridol for schizophrenia. Cochrane Database Syst. Rev. 2006, (2): CD002923. https://doi:10.1002/14651858.CD002923.pub2.González-Rodríguez, A.; Guàrdia, A.; Monreal, J.A. Peri- and post-menopausal women with schizophrenia and related disorders are a population with specific needs: A narrative review of current theories. J. Pers. Med. 2021, 11(9): 849.González-Rodríguez, A.; Guàrdia, A.; Monreal, J.A. Peri- and post-menopausal women with schizophrenia and related disorders are a population with specific needs: A narrative review of current theories. J. Pers. Med. 2021, 11(9): 849.Baeza, I.; Castro-Fornieles, J.; Deulofeu, R. et al. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Psychiatry Res. 2009, 168(2): 110-118.Baeza, I.; Castro-Fornieles, J.; Deulofeu, R. et al. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Psychiatry Res. 2009, 168(2): 110-118.Yasui-Furukori, N.; Kondo, T.; Suzuki, A. et al. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry.2002, 26(3): 575-578.Yasui-Furukori, N.; Kondo, T.; Suzuki, A. et al. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry.2002, 26(3): 575-578.Buckman, M.T.; Peake, G.T. Concordance of insulin-induced hypoglycemia and phenothiazine-induced prolactin secretion in man. J. Clin. Endocrinol. Metab. 1979, 48(2): 21321-21326.Buckman, M.T.; Peake, G.T. Concordance of insulin-induced hypoglycemia and phenothiazine-induced prolactin secretion in man. J. Clin. Endocrinol. Metab. 1979, 48(2): 21321-21326.Abel, K.M.; Drake, R.; Goldstein, J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry. 2010, 22(5): 417-428.Abel, K.M.; Drake, R.; Goldstein, J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry. 2010, 22(5): 417-428.Timdahl, K.; Carlsson, A.; Stening, G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum. Psychopharmacol. 2007, 22(5): 315-325.Timdahl, K.; Carlsson, A.; Stening, G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum. Psychopharmacol. 2007, 22(5): 315-325.Kleppe, R.; Waheed, Q.; Ruoff, P. DOPA Homeostasis by Dopamine: A Control-Theoretic View. Int. J. Mol. Sci. 2021, 22 (23): 12862. https://doi:10.3390/ijms222312862.Kleppe, R.; Waheed, Q.; Ruoff, P. DOPA Homeostasis by Dopamine: A Control-Theoretic View. Int. J. Mol. Sci. 2021, 22 (23): 12862. https://doi:10.3390/ijms222312862.Lee, H.B.; Yoon, B.H.; Kwon, Y.J. et al. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study. Clin. Drug. Investig. 2013, 33(10): 743-53.Lee, H.B.; Yoon, B.H.; Kwon, Y.J. et al. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study. Clin. Drug. Investig. 2013, 33(10): 743-53.Sohler, N.; Adams, B.G.; Barnes, D.M. et al. Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review. Am. J. Orthopsychiatry. 2016, 86(5): 477-485.Sohler, N.; Adams, B.G.; Barnes, D.M. et al. Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review. Am. J. Orthopsychiatry. 2016, 86(5): 477-485.Kulkarni J., Gavrilidis E., Hayes E. et al. Special biological issues in the management of women with schizophrenia. Expert Rev. Neurother. 2012, 12(7): 823-833.Kulkarni J., Gavrilidis E., Hayes E. et al. Special biological issues in the management of women with schizophrenia. Expert Rev. Neurother. 2012, 12(7): 823-833.Leung, A.; Chue, P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. Suppl. 2000, 401: 3-38.Leung, A.; Chue, P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr. Scand. Suppl. 2000, 401: 3-38.Salem, J.E.; Kring, A.M. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clinical Psychology Review. 1998, 18 (7): 795-819.Salem, J.E.; Kring, A.M. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clinical Psychology Review. 1998, 18 (7): 795-819.Seeman, M.V.; Lang, M. The role of estrogens in schizophrenia gender differences. Schizophrenia Bulletin. 1990, 16: 185-194.Seeman, M.V.; Lang, M. The role of estrogens in schizophrenia gender differences. Schizophrenia Bulletin. 1990, 16: 185-194.Meltzer, H.Y.; Lindenmayer, J.P.; Kay, S.R. The role of dopamine in schizophrenia. New biological vistas on schizophrenia. New York: Bruner/Mazel. 1992, 131-157.Meltzer, H.Y.; Lindenmayer, J.P.; Kay, S.R. The role of dopamine in schizophrenia. New biological vistas on schizophrenia. New York: Bruner/Mazel. 1992, 131-157.Heitmiller, D.R.; Nopoulos, P.C.; Andreasen, N.C. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr. Res. 2004, 66, 137-142.Heitmiller, D.R.; Nopoulos, P.C.; Andreasen, N.C. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr. Res. 2004, 66, 137-142.Parellada, E.; Lomena, F.; Catafau, A.M. et al. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naïve schizophrenic patients: an IBZM-SPECT study. Psych. Res. 2004, 130: 79-84.Parellada, E.; Lomena, F.; Catafau, A.M. et al. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naïve schizophrenic patients: an IBZM-SPECT study. Psych. Res. 2004, 130: 79-84.Abel, K.M.; Drake, R.; Goldstein, J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry. 2010, 22 (5): 417-428.Abel, K.M.; Drake, R.; Goldstein, J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry. 2010, 22 (5): 417-428.Salokangas R.K. Gender and the use of neuroleptics in schizophrenia. Further testing of the estrogen hypothesis. Schizophr. Res. 1995, 16(1): 7-16.Salokangas R.K. Gender and the use of neuroleptics in schizophrenia. Further testing of the estrogen hypothesis. Schizophr. Res. 1995, 16(1): 7-16.Capdevielle, D.; Ritchie, K.; Villebrun, D. Schizophrenic patients' length of stay: clinical factors of variability and consequences. Encephale. 2009, 35(1): 90-96.Capdevielle, D.; Ritchie, K.; Villebrun, D. Schizophrenic patients' length of stay: clinical factors of variability and consequences. Encephale. 2009, 35(1): 90-96.Kim, Y.; Kim, B.N.; Cho, S.C. et al. Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: a retrospective study in Korean children and adolescents. Hum. Psychopharmacol. 2008, 23(8): 715-722.Kim, Y.; Kim, B.N.; Cho, S.C. et al. Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: a retrospective study in Korean children and adolescents. Hum. Psychopharmacol. 2008, 23(8): 715-722.Vilianov, V.B. Gender factor and the effectiveness of modern antipsychotics in the treatment of patients with schizophrenia. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2004, 2: 18-20. (In Russ.).Vilianov, V.B. Gender factor and the effectiveness of modern antipsychotics in the treatment of patients with schizophrenia. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2004, 2: 18-20. (In Russ.).Gleeson, P.C.; Worsley, R.; Gavrilidis, E. et al. Menstrual cycle characteristics in women with persistent schizophrenia. Aust. N. Z. J. Psychiatry. 2016, 50(5): 481-487.Gleeson, P.C.; Worsley, R.; Gavrilidis, E. et al. Menstrual cycle characteristics in women with persistent schizophrenia. Aust. N. Z. J. Psychiatry. 2016, 50(5): 481-487.Woods, S.W.; Gueorguieva, R.V.; Baker, C.B. et al. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch. Gen. Psychiatry. 2005, 62(9): 961-970.Woods, S.W.; Gueorguieva, R.V.; Baker, C.B. et al. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch. Gen. Psychiatry. 2005, 62(9): 961-970.Alisch, J.S.R.; Kiely, M.; Triebswetter, C.; Alsameen, M.H.; Gong, Z.; Khattar, N.; Egan, J.M.; Bouhrara, M. et al. Characterization of age-related differences in the human choroid plexus volume, microstructural integrity, and blood perfusion using multiparameter magnetic resonance imaging. Front. Aging Neurosci. 2021, 13: 734992. doi:10.3389/fnagi.2021.734992.Alisch, J.S.R.; Kiely, M.; Triebswetter, C.; Alsameen, M.H.; Gong, Z.; Khattar, N.; Egan, J.M.; Bouhrara, M. et al. Characterization of age-related differences in the human choroid plexus volume, microstructural integrity, and blood perfusion using multiparameter magnetic resonance imaging. Front. Aging Neurosci. 2021, 13: 734992. doi:10.3389/fnagi.2021.734992.Maioli, S.; Leander, K.; Nilsson, P. et al. Estrogen receptors and the aging brain. Essays Biochem. 2021, 65(6): 913-925.Maioli, S.; Leander, K.; Nilsson, P. et al. Estrogen receptors and the aging brain. Essays Biochem. 2021, 65(6): 913-925.Wong, J.O.; Leung, S.P.; Mak, T. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006, 30(2): 251-264.Wong, J.O.; Leung, S.P.; Mak, T. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006, 30(2): 251-264.Varghese, M.T.; Jyothi, K.S.; Shaji, K.S. et al. Delaying clozapine: How long is too long? Gen. Psychiatr. 2020, 33(2): e100172. https://doi:10.1136/gpsych-2019-100172.Varghese, M.T.; Jyothi, K.S.; Shaji, K.S. et al. Delaying clozapine: How long is too long? Gen. Psychiatr. 2020, 33(2): e100172. https://doi:10.1136/gpsych-2019-100172.Haring, C.; Meise, U.; Humpel, C. еt al. Dose-related plasma levels of clozapine: Influence of smoking, behavior, sex and age. Psychopharmacology. 1989, 99: 38-40.Haring, C.; Meise, U.; Humpel, C. еt al. Dose-related plasma levels of clozapine: Influence of smoking, behavior, sex and age. Psychopharmacology. 1989, 99: 38-40.Khan, Z.; Miller, E.A.; Pervaiz, A.M. Clozapine intoxication in a patient on chronic use with a short-term noncompliance. Cureus. 2021, 13(7): e16578. https://doi:10.7759/cureus.16578.Khan, Z.; Miller, E.A.; Pervaiz, A.M. Clozapine intoxication in a patient on chronic use with a short-term noncompliance. Cureus. 2021, 13(7): e16578. https://doi:10.7759/cureus.16578.Frogley, C.; Taylor, D.; Dickens, G. et al. A systematic review of the evidence of clozapine's anti-aggressive effects. Int. J. Neuropsychopharmacol. 2012, 15(9): 1351-1371.Frogley, C.; Taylor, D.; Dickens, G. et al. A systematic review of the evidence of clozapine's anti-aggressive effects. Int. J. Neuropsychopharmacol. 2012, 15(9): 1351-1371.Suzuki, T.; Uchida, H.; Watanabe, K. et al. Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol. Bull. 2011, 44(1): 32-60.Suzuki, T.; Uchida, H.; Watanabe, K. et al. Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol. Bull. 2011, 44(1): 32-60.Goldstein, J. M.; Cohen, L.S.; Horton, N. J. еt al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Research. 2002, 110, 27-37.Goldstein, J. M.; Cohen, L.S.; Horton, N. J. еt al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Research. 2002, 110, 27-37.Gorobets, L.N., Mazo, G.E. Neuroendocrine dysfunctions when using psychopharmacotherapy. Regional psychopharmacotherapy in psychiatry: Guidelines for practicing physicians. Ed. Yu.A. Alexandrovsky and N.G. Neznanov. Moscow: Litera. 2014, 802- 823. (In Russ.).Gorobets, L.N., Mazo, G.E. Neuroendocrine dysfunctions when using psychopharmacotherapy. Regional psychopharmacotherapy in psychiatry: Guidelines for practicing physicians. Ed. Yu.A. Alexandrovsky and N.G. Neznanov. Moscow: Litera. 2014, 802- 823. (In Russ.).Kleinberg, D.L.; Davis, J.M.; De Coster, R. Prolactine levels and adverse events in patients treated with risperidone. Clin. Psychopharmacology. 1999, 19, 57-64.Kleinberg, D.L.; Davis, J.M.; De Coster, R. Prolactine levels and adverse events in patients treated with risperidone. Clin. Psychopharmacology. 1999, 19, 57-64.David, S.R.; Taylor, C.C.; Kinon, B.J. еt al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics. 2000, 22: 1085-1096.David, S.R.; Taylor, C.C.; Kinon, B.J. еt al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics. 2000, 22: 1085-1096.Basson, B.R.; Kinon, B.J.; Taylor, C.C. еt al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Journal of Clinical Psychiatry. 2001, 62, 231-238.Basson, B.R.; Kinon, B.J.; Taylor, C.C. еt al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Journal of Clinical Psychiatry. 2001, 62, 231-238.Grunder, G.; Wetzel, H.; Schlosser, R. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol. Psychiatry. 1999, 45(1), 89-97.Grunder, G.; Wetzel, H.; Schlosser, R. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol. Psychiatry. 1999, 45(1), 89-97.Bobes, J.; Rejas, J.; Garcia-Garcia, M. еt al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophrenia Research. 2003, 62: 77-88.Bobes, J.; Rejas, J.; Garcia-Garcia, M. еt al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophrenia Research. 2003, 62: 77-88.Reiser, L.W.; Reiser, M.F. Endocrine disorders. Comprehensive Textbook of Psychiatry. New York. 1984, 1024-1035.Reiser, L.W.; Reiser, M.F. Endocrine disorders. Comprehensive Textbook of Psychiatry. New York. 1984, 1024-1035.

The authors declare that there are no conflicts of interest present.